JP2009534455A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009534455A5 JP2009534455A5 JP2009507156A JP2009507156A JP2009534455A5 JP 2009534455 A5 JP2009534455 A5 JP 2009534455A5 JP 2009507156 A JP2009507156 A JP 2009507156A JP 2009507156 A JP2009507156 A JP 2009507156A JP 2009534455 A5 JP2009534455 A5 JP 2009534455A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutical composition
- tumor
- composition according
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 239000011435 rock Substances 0.000 claims 7
- 208000024891 symptom Diseases 0.000 claims 7
- 206010027476 Metastases Diseases 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 230000009401 metastasis Effects 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 206010006187 Breast cancer Diseases 0.000 claims 5
- 208000026310 Breast neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- -1 hydroxy, amino, methylamino, dimethylamino, methoxy Chemical group 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 230000009545 invasion Effects 0.000 claims 4
- 125000005647 linker group Chemical group 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 102000036365 BRCA1 Human genes 0.000 claims 3
- 108700020463 BRCA1 Proteins 0.000 claims 3
- 101150072950 BRCA1 gene Proteins 0.000 claims 3
- 108091000080 Phosphotransferase Proteins 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 102000020233 phosphotransferase Human genes 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 102000052609 BRCA2 Human genes 0.000 claims 2
- 108700020462 BRCA2 Proteins 0.000 claims 2
- 101150008921 Brca2 gene Proteins 0.000 claims 2
- 108010092160 Dactinomycin Proteins 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 206010061309 Neoplasm progression Diseases 0.000 claims 2
- 102000001253 Protein Kinase Human genes 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 229930183665 actinomycin Natural products 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 230000003321 amplification Effects 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 210000000349 chromosome Anatomy 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000008602 contraction Effects 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 238000002405 diagnostic procedure Methods 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 108060006633 protein kinase Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 230000005751 tumor progression Effects 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000032320 Germ cell tumor of testis Diseases 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 claims 1
- 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 claims 1
- 206010064390 Tumour invasion Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000009400 cancer invasion Effects 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000010307 cell transformation Effects 0.000 claims 1
- 230000019522 cellular metabolic process Effects 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 claims 1
- JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000002918 testicular germ cell tumor Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0608176.4 | 2006-04-25 | ||
| GB0608179.8 | 2006-04-25 | ||
| GB0608179A GB0608179D0 (en) | 2006-04-25 | 2006-04-25 | Pharmaceutical compounds |
| GB0608176A GB0608176D0 (en) | 2006-04-25 | 2006-04-25 | Pharmaceutical Compounds |
| PCT/GB2007/001518 WO2007125321A2 (en) | 2006-04-25 | 2007-04-25 | Purine and deazapurine derivatives as pharmaceutical compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009534455A JP2009534455A (ja) | 2009-09-24 |
| JP2009534455A5 true JP2009534455A5 (enExample) | 2010-06-17 |
| JP5606734B2 JP5606734B2 (ja) | 2014-10-15 |
Family
ID=38255445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009507156A Active JP5606734B2 (ja) | 2006-04-25 | 2007-04-25 | 医薬化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8796293B2 (enExample) |
| EP (3) | EP3719018B1 (enExample) |
| JP (1) | JP5606734B2 (enExample) |
| DK (2) | DK3719018T3 (enExample) |
| ES (2) | ES2878130T3 (enExample) |
| FI (1) | FI3719018T3 (enExample) |
| WO (1) | WO2007125321A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| WO2007125321A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
| US8227603B2 (en) * | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
| US8299248B2 (en) * | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| BRPI0714725B1 (pt) * | 2006-08-02 | 2021-05-25 | Cytokinetics, Inc | Entidade química, composição farmaceuticamente aceitável, e, uso de uma entidade química |
| US7851484B2 (en) | 2007-03-30 | 2010-12-14 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| UA99284C2 (ru) | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
| BRPI0818533B8 (pt) | 2007-10-11 | 2021-05-25 | Astrazeneca Ab | composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto |
| US8173635B2 (en) | 2007-11-02 | 2012-05-08 | Vertex Pharmaceuticals Incorporated | Kinase inhibitors |
| WO2009089352A1 (en) | 2008-01-08 | 2009-07-16 | Array Biopharma Inc. | Pyrrolopyridines as kinase inhibitors |
| EP2242757B1 (en) | 2008-01-09 | 2012-08-01 | Array Biopharma, Inc. | Pyrazolopyridines as kinase inhibitors |
| EP2297153B1 (en) * | 2008-04-21 | 2015-05-27 | Lexicon Pharmaceuticals, Inc. | Limk2 inhibitors, compositions comprising them, and methods of their use |
| CL2009001152A1 (es) | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
| AU2013218743B2 (en) * | 2008-05-13 | 2016-04-28 | Array Biopharma Inc. | Pyrrolopyridines as kinase inhibitors |
| GB0906579D0 (en) * | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
| AR074072A1 (es) | 2008-11-11 | 2010-12-22 | Lilly Co Eli | Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme |
| BR112012011328A2 (pt) | 2009-10-23 | 2016-11-22 | Lilly Co Eli | inibidores de akt |
| BR112012019459A2 (pt) | 2010-02-03 | 2017-10-17 | Signal Pharm Llc | identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase. |
| PL2651417T3 (pl) | 2010-12-16 | 2017-08-31 | Calchan Limited | Pochodne pirolopirymidyny hamujące ASK1 |
| ME03589B (me) | 2011-04-01 | 2020-07-20 | Astrazeneca Ab | Terapeutski tretman |
| CN109316480A (zh) | 2011-07-13 | 2019-02-12 | 赛特凯恩蒂克公司 | 组合als疗法 |
| ES2646759T3 (es) * | 2011-09-12 | 2017-12-15 | Merck Patent Gmbh | Derivados de aminopirimidina para uso como moduladores de la actividad de la quinasa |
| JP6105594B2 (ja) | 2011-09-30 | 2017-03-29 | エンドゥ ファーマシューティカルズ，インコーポレイティド | 癌処置用ｃｙｐ１７阻害剤としてのイミダゾール誘導体 |
| JP6130383B2 (ja) | 2011-09-30 | 2017-05-17 | エンドゥ ファーマシューティカルズ，インコーポレイティド | ピリジン誘導体 |
| MX367640B (es) | 2011-11-30 | 2019-08-29 | Astrazeneca Ab | Tratamiento combinado del cáncer. |
| AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| BR112015007513A2 (pt) * | 2012-10-26 | 2017-07-04 | Hoffmann La Roche | inibidores de tirosina quinase de bruton |
| WO2014086453A1 (en) * | 2012-12-07 | 2014-06-12 | Merck Patent Gmbh | Azaheterobicyclic compounds |
| WO2014172436A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
| WO2014172425A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| CA2908742C (en) | 2013-04-17 | 2021-06-01 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer |
| JP6382946B2 (ja) | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ，エルエルシー | ジヒドロピラジノ−ピラジンによる癌治療 |
| HK1221168A1 (zh) | 2013-04-17 | 2017-05-26 | 西格诺药品有限公司 | 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法 |
| MY189663A (en) | 2013-04-17 | 2022-02-23 | Signal Pharm Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
| EP3549940A1 (en) | 2013-04-17 | 2019-10-09 | Signal Pharmaceuticals, LLC | Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
| CN107474051B (zh) | 2013-05-29 | 2020-10-30 | 西格诺药品有限公司 | 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途 |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| WO2015160880A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2016139212A1 (en) * | 2015-03-04 | 2016-09-09 | F. Hoffmann-La Roche Ag | Triazolopyridine compounds and methods of use thereof |
| IL271491B2 (en) | 2017-06-22 | 2023-09-01 | Celgene Corp | Treatment of carcinoma of the liver characterized by hepatitis b virus infection |
| WO2021143680A1 (zh) | 2020-01-16 | 2021-07-22 | 浙江海正药业股份有限公司 | 杂芳基类衍生物及其制备方法和用途 |
| CA3169944A1 (en) * | 2020-03-25 | 2021-09-30 | Thomas Macallister | Methods of using rho kinase inhibitors to treat frontotemporal dementia |
| AU2020480829A1 (en) | 2020-12-07 | 2023-07-20 | Kimberly-Clark Worldwide, Inc. | Methods and consumer products for detecting a metabolite |
| MX2024011674A (es) * | 2022-03-24 | 2024-09-27 | Curasen Therapeutics Inc | Agonistas del receptor a1a-adrenérgico y métodos de uso. |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL297170A (enExample) | 1963-04-04 | 1900-01-01 | ||
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| IT1252567B (it) | 1991-12-20 | 1995-06-19 | Italfarmaco Spa | Derivati di 5-isochinolinsolfonammidi inibitori delle protein-chinasi |
| GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| EP0944388A4 (en) | 1996-04-03 | 2001-08-16 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
| CA2744096C (en) | 1996-07-31 | 2013-07-30 | Laboratory Corporation Of America Holdings | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
| WO1999007703A1 (en) | 1997-08-05 | 1999-02-18 | Pfizer Products Inc. | 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS |
| US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| HUP0103836A3 (en) | 1998-06-02 | 2003-05-28 | Osi Pharmaceuticals Inc Uniond | Pyrrolo[2,3d]pyrimidine compositions and their use |
| AU4231299A (en) | 1998-06-04 | 1999-12-20 | Abbott Laboratories | Cell adhesion-inhibiting antinflammatory compounds |
| PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| AU3951899A (en) | 1998-06-19 | 2000-01-05 | Pfizer Products Inc. | Pyrrolo(2,3-d)pyrimidine compounds |
| US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
| HK1045306A1 (zh) | 1999-06-03 | 2002-11-22 | Abbott Laboratories | 抑制细胞黏附的抗炎化合物 |
| US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| US6610688B2 (en) * | 1999-12-21 | 2003-08-26 | Sugen, Inc. | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
| KR100602929B1 (ko) | 2000-08-31 | 2006-07-20 | 에프. 호프만-라 로슈 아게 | 알파-1 아드레날린성 길항제로서 퀴나졸린 유도체 |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| BR0115847A (pt) | 2000-12-01 | 2004-02-25 | Osi Pharm Inc | Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos |
| US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| DE60305446T4 (de) | 2002-01-07 | 2009-07-09 | Eisai R&D Management Co., Ltd. | Desazapurine und deren verwendung |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| DK1522314T3 (da) | 2002-06-26 | 2014-05-26 | Ono Pharmaceutical Co | Midler for sygdomme forårsaget af vaskulær sammentrækning eller udvidelse |
| US20040138238A1 (en) | 2002-08-08 | 2004-07-15 | Dhanoa Dale S. | Substituted aminopyrimidine compounds as neurokinin antagonists |
| US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US20060159617A1 (en) | 2002-11-08 | 2006-07-20 | Ashfaq Mahmood | Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors |
| AU2003302657B8 (en) | 2002-12-04 | 2009-12-03 | Eisai R&D Management Co., Ltd. | Fused 1,3-dihydroimidazole ring compounds |
| EP1444982A1 (de) * | 2003-02-06 | 2004-08-11 | Merckle Gmbh | Verwendung von Purinderivaten als selektive Kinase-Inhibitoren |
| SE0300457D0 (sv) | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
| MXPA05009722A (es) | 2003-03-10 | 2006-03-09 | Schering Corp | Inhibidores heterociclicos de cinasa: metodos de uso y sintesis. |
| AU2004232392A1 (en) | 2003-04-21 | 2004-11-04 | Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky | (Purin-6-yl) amino acid and production method thereof |
| FR2856685B1 (fr) | 2003-06-25 | 2005-09-23 | Merck Sante Sas | Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2005020921A2 (en) | 2003-08-29 | 2005-03-10 | Exelixis, Inc. | C-kit modulators and methods of use |
| WO2005044181A2 (en) | 2003-09-09 | 2005-05-19 | Temple University-Of The Commonwealth System Of Higher Education | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors |
| TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| AU2004293026B2 (en) | 2003-11-21 | 2012-01-19 | Array Biopharma Inc. | AKT protein kinase inhibitors |
| WO2005063704A1 (ja) | 2003-12-25 | 2005-07-14 | Ono Pharmaceutical Co., Ltd. | アゼチジン環化合物およびその医薬 |
| WO2005117909A2 (en) * | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| MY179032A (en) * | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| AU2005322085B2 (en) * | 2004-12-28 | 2012-07-19 | Exelixis, Inc. | [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| FR2880626B1 (fr) * | 2005-01-13 | 2008-04-18 | Aventis Pharma Sa | Derives de la purine, compositions les contenant et utilisation |
| FR2880540B1 (fr) * | 2005-01-13 | 2008-07-11 | Aventis Pharma Sa | Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 |
| US7423043B2 (en) * | 2005-02-18 | 2008-09-09 | Lexicon Pharmaceuticals, Inc. | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds |
| US20060281768A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
| JP5071374B2 (ja) * | 2005-07-14 | 2012-11-14 | アステラス製薬株式会社 | ヘテロ環ヤヌスキナーゼ３阻害剤 |
| US20070049591A1 (en) * | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
| WO2007084667A2 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
| JP2009534456A (ja) | 2006-04-25 | 2009-09-24 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| EP2037931A2 (en) | 2006-04-25 | 2009-03-25 | Astex Therapeutics Limited | Pharmaceutical combinations of pk inhibitors and other active agents |
| JP2009534454A (ja) | 2006-04-25 | 2009-09-24 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| WO2007125321A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
| US20090253718A1 (en) | 2006-04-25 | 2009-10-08 | Astex Therapeutics Limited | Pharmaceutical Compounds |
| AR064415A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb. |
| AR064416A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
| BRPI0818533B8 (pt) | 2007-10-11 | 2021-05-25 | Astrazeneca Ab | composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto |
-
2007
- 2007-04-25 WO PCT/GB2007/001518 patent/WO2007125321A2/en not_active Ceased
- 2007-04-25 EP EP19216213.9A patent/EP3719018B1/en active Active
- 2007-04-25 DK DK19216213.9T patent/DK3719018T3/da active
- 2007-04-25 FI FIEP19216213.9T patent/FI3719018T3/fi active
- 2007-04-25 DK DK18182786.6T patent/DK3421471T3/da active
- 2007-04-25 EP EP07732555A patent/EP2043655A2/en not_active Withdrawn
- 2007-04-25 EP EP18182786.6A patent/EP3421471B1/en active Active
- 2007-04-25 ES ES18182786T patent/ES2878130T3/es active Active
- 2007-04-25 ES ES19216213T patent/ES3043833T3/es active Active
- 2007-04-25 JP JP2009507156A patent/JP5606734B2/ja active Active
- 2007-04-25 US US12/298,462 patent/US8796293B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009536161A5 (enExample) | ||
| JP2009536620A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| PH12013501221A1 (en) | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | |
| CA2919948A1 (en) | Novel quinazolinones as bromodomain inhibitors | |
| JP2017509586A5 (enExample) | ||
| JP2011515397A5 (enExample) | ||
| JP2018536705A5 (enExample) | ||
| MY156747A (en) | Isoxazolo-pyridine derivatives | |
| ATE507204T1 (de) | Isoindolin-verbindungen und deren verwendungen | |
| CO6561821A2 (es) | Compuesto n-(1h-indazol-4-il)imidazol[1.2-a]piridin -3-carboxamida sustituidos como inhibidores de cfms | |
| UA116774C2 (uk) | Інгібітори серин/треонінкінази | |
| CY1117045T1 (el) | Ενωσεις κινουκλιδινης ως προσδετες του νικοτινικου υποδοχεα ακετυλχολινης αλφα-7 | |
| JP2016538257A5 (enExample) | ||
| RU2016118768A (ru) | Композиции, пригодные для лечения расстройств, связанных с kit | |
| JP2008505167A5 (enExample) | ||
| Vasbinder et al. | Discovery and Optimization of a Novel Series of Potent Mutant B‑RafV600E Selective Kinase Inhibitors | |
| JP2019501140A5 (enExample) | ||
| CN107531633A (zh) | 5‑芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途 | |
| JP2016531126A5 (enExample) | ||
| JP2017502092A5 (enExample) | ||
| PL1891029T3 (pl) | Związki organiczne do leczenia stanów zapalnych lub alergicznych | |
| JP2024125139A5 (enExample) | ||
| KR20200118037A (ko) | 암 또는 염증성 질환들을 치료하기 위한 헤테로비시클릭 카르복시산들 | |
| CA3000565C (en) | 2-aminoquinazoline derivatives as p70s6 kinase inhibitors |